Punt CJ - Search Results

1

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, Vink-Börger ME, van Vliet S, Teerenstra S, Kamping E, Verwiel E, Koopman M, Meijer GA, van Krieken JH, Kuiper R, Punt CJ, Nagtegaal ID. Mekenkamp LJ, et al. Among authors: punt cj. BMC Cancer. 2012 Jul 17;12:292. doi: 10.1186/1471-2407-12-292. BMC Cancer. 2012. PMID: 22804917 Free PMC article.

2

Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.

Punt CJ, de Mulder PH, Burghouts JT, Wagener DJ. Punt CJ, et al. Cancer Chemother Pharmacol. 1992;29(4):326-8. doi: 10.1007/BF00685954. Cancer Chemother Pharmacol. 1992. PMID: 1537082 Clinical Trial.

3

Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.

Punt CJ, Burghouts JT, Croles JJ, van Liessum PA, de Mulder PH, Kamm Y. Punt CJ, et al. Cancer. 1993 Oct 1;72(7):2107-11. doi: 10.1002/1097-0142(19931001)72:7<2107::aid-cncr2820720708>3.0.co;2-m. Cancer. 1993. PMID: 8374869 Clinical Trial.

4

Tallimustine in advanced previously untreated colorectal cancer, a phase II study.

Punt CJ, Humblet Y, Roca E, Dirix LY, Wainstein R, Polli A, Corradino I. Punt CJ, et al. Br J Cancer. 1996 Mar;73(6):803-4. doi: 10.1038/bjc.1996.140. Br J Cancer. 1996. PMID: 8611384 Free PMC article. Clinical Trial.

5

Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.

Punt CJ, Kamm YL, Wagener DJ. Punt CJ, et al. Anticancer Drugs. 1997 Jun;8(5):454-8. doi: 10.1097/00001813-199706000-00006. Anticancer Drugs. 1997. PMID: 9215607

6

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.

Punt CJ, van Herpen CM, Jansen RL, Vreugdenhil G, Muller EW, de Mulder PH. Punt CJ, et al. Br J Cancer. 1997;76(2):266-9. doi: 10.1038/bjc.1997.374. Br J Cancer. 1997. PMID: 9231931 Free PMC article. Clinical Trial.

7

Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Punt CJ, Voest EE, Tueni E, Van Oosterom AT, Backx A, De Mulder PH, Hecquet B, Lucas C, Gerard B, Bleiberg H. Punt CJ, et al. Br J Cancer. 1997;76(10):1376-81. doi: 10.1038/bjc.1997.563. Br J Cancer. 1997. PMID: 9374386 Free PMC article. Clinical Trial.

8

5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules.

Kamm YJ, Wagener DJ, Rietjens IM, Punt CJ. Kamm YJ, et al. Among authors: punt cj. Anticancer Drugs. 1998 Jun;9(5):371-80. doi: 10.1097/00001813-199806000-00001. Anticancer Drugs. 1998. PMID: 9660532 Review.

9

New drugs in the treatment of colorectal carcinoma.

Punt CJ. Punt CJ. Cancer. 1998 Aug 15;83(4):679-89. doi: 10.1002/(sici)1097-0142(19980815)83:4<679::aid-cncr8>3.0.co;2-f. Cancer. 1998. PMID: 9708931 Review.

10

Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.

Punt CJ, Keizer HJ, Douma J, Skovsgaard T, Schüller J, Muller EW, Ten Napel CH, Croles JJ, Lochs H, Zhang J, Hammershaimb L. Punt CJ, et al. Ann Oncol. 2002 Jan;13(1):81-6. doi: 10.1093/annonc/mdf045. Ann Oncol. 2002. PMID: 11865814 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

485 results

Search Page